Skip to main content

Leukotriene Modifiers

  • Chapter
  • 996 Accesses

Abstract

Leukotriene modifiers represent a potentially useful agent in the treatment of chronic rhinosinusitis. Currently, leukotriene-modifying agents are FDA approved for treatment of asthma and allergic rhinitis. Leukotrienes are inflammatory agents released by mast cells and eosinophils. They enact inflammatory changes by increasing edema, recruiting inflammatory cells, increasing cytokine and collagen production, and increasing vascular permeability. Leukotriene-modifying agents include leukotriene receptor antagonists and 5-lipoxygenase inhibitors, both of which act to decrease downstream leukotriene effects. Currently, there are no specific guidelines for the use of antileukotriene agents in chronic rhinosinusitis. They are often used as adjunct therapy for the medical management of Samter’s (aspirin) triad patients and patients with chronic rhinosinusitis with nasal polyposis. The literature studying the benefits of antileukotrienes in chronic rhinosinusitis is limited, but existing data does show some benefit of using these agents in specific cases.

Keywords

  • Chronic rhinosinusitis
  • Leukotriene
  • Montelukast
  • Allergic rhinitis
  • Aspirin triad
  • Nasal polyposis
  • Montelukast

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-16724-4_18
  • Chapter length: 7 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   169.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-16724-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   219.99
Price excludes VAT (USA)
Hardcover Book
USD   249.99
Price excludes VAT (USA)
Fig. 18.1

References

  1. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887–901.

    CAS  PubMed  CrossRef  Google Scholar 

  2. Cingi C, Gunham K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718–23.

    CAS  PubMed  CrossRef  Google Scholar 

  3. Kennedy JL, Borish L. Chronic sinusitis pathophysiology: the role of allergy. Am J Rhinol Allergy. 2013;27(5):367–71.

    PubMed Central  PubMed  CrossRef  Google Scholar 

  4. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986;16:289–97.

    CAS  PubMed  CrossRef  Google Scholar 

  5. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005;127:1312–26.

    CAS  PubMed  CrossRef  Google Scholar 

  6. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy. 2000;55:7–16.

    PubMed  CrossRef  Google Scholar 

  7. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280–9.

    PubMed  CrossRef  Google Scholar 

  8. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23(3):1–298.

    Google Scholar 

  9. Cain RB, Lal D. Update on the management of chronic rhinosinusitis. Infect Drug Resist. 2013;6:1–14.

    PubMed Central  PubMed  Google Scholar 

  10. Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. 2007;137:S1–31.

    PubMed  CrossRef  Google Scholar 

  11. Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochim Biophys Acta. 2011;1810(11):1096–102.

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  12. Peters-Golden M, Henderson Jr WR. Leukotrienes. N Engl J Med. 2007;357(18):1841–54.

    CAS  PubMed  CrossRef  Google Scholar 

  13. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy. 2002;32(7):1007–12.

    CAS  PubMed  CrossRef  Google Scholar 

  14. Chao SS, Graham SM, Brown CL, et al. Cysteinyl leukotriene 1 receptor expression in nasal polyps. Ann Otol Rhinol Laryngol. 2006;115(5):394–7.

    PubMed  CrossRef  Google Scholar 

  15. Pauli C, Fintelmann R, Klemens C, et al. Polyposis nasi – improvement in quality of life by the influence of leukotriene receptor antagonists. Laryngorhinootologie. 2007;86(4):282–6.

    CAS  PubMed  CrossRef  Google Scholar 

  16. Schaper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21(1):51–8.

    CAS  PubMed  Google Scholar 

  17. Kutting B, Nieschalk M, Brehler R. A new concept for treatment of sinonasal polyposis. Allergy. 2000;55(11):1091–2.

    CAS  PubMed  CrossRef  Google Scholar 

  18. Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M. Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2005;67(3):148–53.

    CAS  PubMed  CrossRef  Google Scholar 

  19. Vuralkan E, Saka C, Akin I, Hucumenoglu S, et al. Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps. Ther Adv Respir Dis. 2012;6(1):5–10.

    CAS  PubMed  CrossRef  Google Scholar 

  20. Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J. 2000;79(1):18–20.

    CAS  PubMed  Google Scholar 

  21. Nonaka M, Sakanushi A, Kusama K, et al. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J Nippon Med Sch. 2010;77(1):21–8.

    CAS  PubMed  CrossRef  Google Scholar 

  22. Kieff DA, Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol. 2005;114(12):941–5.

    PubMed  CrossRef  Google Scholar 

  23. Stewart RA, Ram B, Hamilton G, et al. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg. 2008;139(5):682–7.

    PubMed  CrossRef  Google Scholar 

  24. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31(9):1385–91.

    CAS  PubMed  CrossRef  Google Scholar 

  25. Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78(8):604–6.

    CAS  PubMed  Google Scholar 

  26. Wentzel JL, Soler ZM, Deyoung K, et al. Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review. Am J Rhinol Allergy. 2013;27(6):482–9.

    PubMed Central  PubMed  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark A. Zacharek MD, FACS .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zacharek, M.A., Birkeland, A.C. (2015). Leukotriene Modifiers. In: Batra, P., Han, J. (eds) Practical Medical and Surgical Management of Chronic Rhinosinusitis. Springer, Cham. https://doi.org/10.1007/978-3-319-16724-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16724-4_18

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16723-7

  • Online ISBN: 978-3-319-16724-4

  • eBook Packages: MedicineMedicine (R0)